Precision medicine in COPD: review of mepolizumab for eosinophilic COPD

Mepolizumab can reduce exacerbation rates in those with frequently exacerbating, severe COPD and raised blood eosinophils; this represents a further advance in precision medicine for COPD and targeted therapies http://ow.ly/uklu30m4YcU

Detalles Bibliográficos
Autores principales: Long, Gabriella, Wall, Jasmine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2018
Materias:
Expert Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269176/
https://www.ncbi.nlm.nih.gov/pubmed/30519304
http://dx.doi.org/10.1183/20734735.026318
Descripción
Sumario:Mepolizumab can reduce exacerbation rates in those with frequently exacerbating, severe COPD and raised blood eosinophils; this represents a further advance in precision medicine for COPD and targeted therapies http://ow.ly/uklu30m4YcU

Ejemplares similares